DAMATO NICOLE sold $207K of INNV

DAMATO NICOLE (CHIEF LEGAL OFFICER) sold 23,814 shares of InnovAge Holding Corp. (INNV) at $8.70 ($0.21M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DAMATO NICOLE
Published Sep 29, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INNV
Bearish
medium confidence
Mentioned
$INNV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INNVBearishLow
01

Why it matters

The disclosed sale is modest and likely to cause only short‑term price pressure.

02

Market read

A routine insider sale with limited material impact; traders may monitor for any follow‑on activity.

03

What to watch

The insider retains a large stake (304,897 shares) and the sale price matches recent market levels.

Relevance 3/10Novelty 3/10Timing: post-market filing today

Background

Form 4 filings provide transparent disclosure of insider transactions, often used by traders to gauge sentiment.

Company-level read

Ticker impact

$INNVBearishMedium confidence
Context

Chief Legal Officer sold 23,814 shares for $207,181, a 10b5-1 plan sale disclosed on Form 4.

Expected impact

likely modest pressure as the market prices in the insider sell.

Evidence & confidence

Sale size is modest relative to holdings, but insider selling can prompt short-term downside bias.

Market effects

Minimal impact on the broader healthcare sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale may be routine under a pre‑arranged plan and not indicative of company outlook.

Key entities

  • InnovAge Holding Corp.

    US‑listed biotech firm (NASDAQ: INNV).

  • Nicole Damato

    Chief Legal Officer of InnovAge.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INNVMed

InnovAge settles DOJ civil claims for $37 million

InnovAge Holding Corp. (INNV) settled civil claims with the DOJ for $37 million, covering alleged conduct from 2016 to 2022. The company did not admit wrongdoing. InnovAge provides senior healthcare programs and has invested in compliance and operations. As of September 2026, it served 8,420 participants across 20 centers in six states.

$INNVMed

InnovAge (INNV) Q1 2027 Earnings Call Transcript

InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.

$INNVMed

What InnovAge (INNV) Said on Its Q1 Earnings Call

InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.

$INNVHigh

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare